Alaa H Falemban, Radhi M Alanazi, Safaa M Alsanosi, Halah T Albar, Asim M Alshanberi, Yosra Z Alhindi
{"title":"Investigating doctors implementation of ACC/AHA blood cholesterol treatment recommendations at a tertiary hospital in Northern Saudi Arabia","authors":"Alaa H Falemban, Radhi M Alanazi, Safaa M Alsanosi, Halah T Albar, Asim M Alshanberi, Yosra Z Alhindi","doi":"10.54905/disssi.v27i139.e358ms3228","DOIUrl":null,"url":null,"abstract":"Background: The 2018 American College of Cardiology (ACC) and American Heart Association (AHA) updated data on blood cholesterol treatment guidelines showed a significant shift in treating atherosclerotic cardiovascular disease (ASCVD). In 2018, recommendations were adopted to increase the number of persons using statin therapy. Still, real-world observations of how treatment use has changed, especially in Saudi Arabia, have yet to be limited in the literature. Doctors' implementation of ACC/AHA 2018 recommendations regarding prescribing medications has yet to be studied in Saudi Arabia. Aim: To examine doctors' implementation of ACC/AHA 2018 cholesterol recommendations in managing acute atherosclerotic cardiovascular disease patients. Results: Almost 47% of the patients were managed according to the 2018 ACC/AHA recommendations. However, 53% of patients did not take statins. Doctors adhered to the recommendations when working with patients with myocardial issues, in contrast to other events. Of the non-adherent patients, 40% refused the treatment because of their beliefs or fear of the side effects. Conclusion: Our primary analysis concluded that statin recommendations were not given to more than half of the patients with acute atherosclerotic diseases; moreover, some did not receive any statin therapy.","PeriodicalId":18393,"journal":{"name":"Medical Science","volume":"38 1","pages":"0"},"PeriodicalIF":0.5000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54905/disssi.v27i139.e358ms3228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The 2018 American College of Cardiology (ACC) and American Heart Association (AHA) updated data on blood cholesterol treatment guidelines showed a significant shift in treating atherosclerotic cardiovascular disease (ASCVD). In 2018, recommendations were adopted to increase the number of persons using statin therapy. Still, real-world observations of how treatment use has changed, especially in Saudi Arabia, have yet to be limited in the literature. Doctors' implementation of ACC/AHA 2018 recommendations regarding prescribing medications has yet to be studied in Saudi Arabia. Aim: To examine doctors' implementation of ACC/AHA 2018 cholesterol recommendations in managing acute atherosclerotic cardiovascular disease patients. Results: Almost 47% of the patients were managed according to the 2018 ACC/AHA recommendations. However, 53% of patients did not take statins. Doctors adhered to the recommendations when working with patients with myocardial issues, in contrast to other events. Of the non-adherent patients, 40% refused the treatment because of their beliefs or fear of the side effects. Conclusion: Our primary analysis concluded that statin recommendations were not given to more than half of the patients with acute atherosclerotic diseases; moreover, some did not receive any statin therapy.